Oncology prior authorization challenges: what slows your team down and what to do about it

If you work in oncology billing or practice management, you already know that prior authorization in this specialty isn't just complicated. It's a different sport entirely. The stakes are higher, the timelines are compressed, and the consequences of a delayed approval aren't purely financial. They're clinical. A patient waiting for immunotherapy approval isn't just an open A/R item on your aging report. And yet many of the same systemic friction points that plagued oncology practices five years ago are still very much alive, just wearing new clothes. Here's what's actually happening and, more importantly, what your team can do about it.

The multi-drug regimen problem isn't going away

One of the most persistent headaches in oncology prior auth is the multi-drug regimen, specifically when a patient's treatment protocol involves several agents that each require separate authorizations from the same payer. A common NSCLC protocol might combine a checkpoint inhibitor with a platinum-based chemotherapy and a second chemotherapy agent. That's potentially three auth requests, three different medical policies, and three different reviewers who may or may not communicate with each other.

What makes this worse: some payers apply step therapy requirements to individual drugs in the regimen independently, which can create situations where the auth for drug A gets approved while drug B is held pending "failure of first-line alternatives," even when the clinical protocol requires both simultaneously. Your oncologist didn't pull this regimen out of thin air; when it is listed in the NCCN Guidelines for that cancer, cite the listing and its NCCN category of evidence and consensus. That doesn't always matter to an automated review engine.

What actually helps here:

• Submit auths for all drugs in a regimen together and explicitly reference the bundled clinical protocol in each request
• Attach the relevant NCCN guideline page directly (not just cite it, include it)
• Flag regimen interdependency in your clinical notes section; make the reviewer's job easier by connecting the dots explicitly
• Build a library of templated clinical rationale for your most common protocols so your team isn't starting from scratch every time

Biomarker testing is creating a new auth bottleneck

In 2026, precision oncology has moved from "emerging" to standard of care in a meaningful way. That's good news clinically. For your auth team, it's a new layer of complexity. More targeted therapies mean more biomarker-specific approvals, and payers have gotten particular about which biomarker tests they consider acceptable to support a targeted therapy auth.

Consider a hypothetical scenario: your patient has metastatic colorectal cancer, and your oncologist orders a comprehensive genomic profiling test via liquid biopsy. The results support a specific targeted therapy. You submit the prior auth. The payer denies it, not because the drug is inappropriate, but because they only accept tissue-based testing results for that indication, and their policy was updated quietly in June. You didn't know. Nobody told you.

Payers revise their biomarker testing and companion diagnostic policies, and the changes are easy to miss.

Practical steps to stay ahead of this:

• Designate someone on your auth team (or assign it as a rotating responsibility) to review payer medical policy updates monthly for your top 10 payers
• When submitting auths for targeted therapies, always include the methodology and vendor for any biomarker testing; don't assume the reviewer will ask
• If a denial cites testing methodology, check what the payer's policy and the test's FDA labeling say before you appeal. Plasma testing can miss alterations that tissue testing finds: the FDA-approved labeling for one plasma companion diagnostic, Guardant360 CDx, states that a negative plasma result does not assure the tumor is negative and that NSCLC patients who test negative should be reflexed to tissue testing if feasible. The appeal is stronger when the policy or the labeling accepts the test that was used; when it doesn't, ask the oncologist whether tissue testing is feasible
• Consider building a payer-specific companion diagnostic matrix; it sounds tedious, but it saves hours when you're working 30 auths a week

Appeals in oncology: speed matters more than almost anywhere else

Oncology denials are not the place for your standard 30-day appeal workflow. Treatment delays in this patient population carry real clinical consequences, and expedited appeals exist for exactly this. ERISA group health plans must decide an urgent care appeal within 72 hours and must treat a claim as urgent when a physician with knowledge of the patient's condition says it is. Medicare Advantage plans must expedite a reconsideration, decided within 72 hours, when a physician indicates the standard timeframe could seriously jeopardize the patient's life, health or ability to regain maximum function. Plans won't wave a flag and tell you to use these pathways. You have to know to ask.

For clinical urgency appeals, documentation specificity is what wins. A vague letter of medical necessity stating "treatment is medically necessary for patient's condition" won't cut it. What consistently moves oncology appeals is specificity: performance status, prior treatment history, why this drug at this dose on this schedule, why alternatives aren't appropriate for this specific patient, and what happens if treatment is delayed. That last piece is often underused. If your oncologist can articulate the clinical consequence of a two-week delay in plain terms, put it in the appeal letter.

When you're managing a high volume of denials and every week counts, drafting time matters. EZAppeal drafts appeal and prior authorization letters in a few minutes, citing the payer's policy when one is on file, for your team to review and send. Any tool is only as good as the clinical information you feed into it, though. Garbage in, garbage out still applies.

The peer-to-peer request: use it earlier than you think you should

Many billing teams treat peer-to-peer review requests as a last resort before formal appeal. Flip that instinct. In oncology especially, peer-to-peer conversations often resolve denials faster than the written appeal process, and your oncologist carries clinical authority in that conversation that no paperwork can replicate.

The friction is physician time. A few things that help:

• Have your clinical team prep a one-page summary before every peer-to-peer (current performance status, prior lines of therapy, specific contraindications to alternatives, relevant biomarker data)
• Track which payers respond well to peer-to-peers versus which ones use them as a delay tactic; that data helps you triage your time
• Some payers allow advanced practice providers to conduct peer-to-peer reviews in certain situations; know your payer policies on this

Building a more resilient oncology auth workflow

There's no single fix that makes oncology prior auth easy. But there are practices that consistently separate the teams managing it well from the teams constantly putting out fires.

The best oncology billing teams right now are proactive about payer policy changes, they maintain protocol-specific documentation libraries, they use expedited appeal pathways aggressively, and they treat peer-to-peer reviews as a front-line tool. They're also using technology to reduce administrative drag rather than to replace clinical judgment, so the people on the team can focus where they actually add value.

If your oncology auth denials are trending up or your days-to-approval are creeping longer, audit your process before you just work harder. Pull your denial reasons by payer and by drug class. You'll almost always find patterns pointing toward specific, fixable gaps. That's where to start.